Teduglutide, a GLP-2 analog, demonstrated clinical benefit for short bowel syndrome by promoting intestinal adaptation and reducing parenteral nutrition dependence — a gut peptide drug for a devastating surgical condition.
Key findingTeduglutide, a GLP-2 analog, demonstrated clinical benefit for short bowel syndrome by promoting intestinal adaptation and reducing parenteral nutriti
What the researchers found
Teduglutide, a GLP-2 analog, demonstrated clinical benefit for short bowel syndrome by promoting intestinal adaptation and reducing parenteral nutrition dependence — a gut peptide drug for a devastating surgical condition.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2010.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.
Current opinion in molecular therapeutics, 12(6), 798-809
Citation
Yazbeck, Roger. (2010). Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.. Current opinion in molecular therapeutics, 12(6), 798-809.